Designer drug
class of recreational drugs
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids.
Some designer drugs were originally synthesized by academic or industrial researchers and later emerged on the grey market for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Many designer drugs have a short history of human use and have not been thoroughly evaluated in animal or human trials, leading to the possibility of unexpected effects and toxicities.
The development of designer drugs may be considered a subfield of drug design. The exploration of modifications to known active drugs—such as their structural analogues, stereoisomers, and derivatives—yields drugs that may differ significantly in effects from their "parent" drug (e.g., showing different potency or side effects). In some instances, designer drugs have similar pharmacology to existing drugs, but are structurally unrelated. For example, JWH-018 and THC are both CB1 agonists despite lacking substantial structural similarity.
In some jurisdictions, designer drugs may fall under analog acts which impose restrictions upon substances which are substantially chemically or pharmacologically similar to existing controlled substances.
“Designer drug” enters the record as class of recreational drugs. Crown Archives preserves that source wording while asking what Designer, drug and class can confirm, complicate or overturn.
Why this record matters
“Designer drug” is worth following because a concise public description often conceals a longer documentary argument. Here, Designer, drug and class provides the most credible route into that argument.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Sep 17, 2026. The linked authority identifier is Q1200715. None of the 0 selected statements returned an explicit reference.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Designer drug”, its source revision and the description used here.
- Expand the search: follow Designer drug primary sources, Designer drug archive and Designer research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Designer drug”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Designer drug” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.